The United Kingdom and the United States have reached a significant bilateral deal that will ensure no duties on British pharmaceutical shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to raise expenditure on pharmaceuticals through the NHS. This pledge guarantees that import taxes on these vital exports will stay at zero for a period of 36 months.
This agreement comes after previous warnings to significantly raise import taxes on patented pharmaceutical imports, with potential rates discussed reaching double the cost.
"This deal between the Britain bolsters the worldwide climate for cutting-edge drugs and establishes much-needed equity to transatlantic drug exports," a release declared.
Economic Significance
Medicines are one of the UK's largest export categories to the US, which is by far the biggest destination for major British pharmaceutical firms.
Statistics show that in the one-year period to the end of September, the UK sold drugs totaling £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that span.
"This guarantee safeguards employment, boosts investment and paves the way for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement includes several specific pledges from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to stay within budget will be restricted at 15%. Previously, rebates were more than twenty percent.
Recent Tensions
This agreement comes amid a long-running tension between the drug companies and the British authorities over medicine costs and NHS adoption.
The disagreement were intensified by claims that US customers were paying significantly more for the same drugs than patients in the Britain and the EU.
Recently, several major drug company projects in the UK have been halted or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
One official acknowledged that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the past decade.
